38.00Open38.00Pre Close0 Volume19 Open Interest290.00Strike Price0.00Turnover3274.47%IV-2.33%PremiumJan 17, 2025Expiry Date43.73Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9808Delta0.0025Gamma5.62Leverage Ratio-199.2703Theta0.0000Rho-5.51Eff Leverage0.0003Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet